Allergie
- Arachis hypogaea (pinda) allergenen (capsule)
- Arachis hypogaea (pinda) allergenen (pleister)
- Olopatadine / mometasone
- Omalizumab IND
Chronische immuunziekten overig
- Anakinra IND
- Apremilast IND
-
Belimumab
- Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody- positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy. IND
- Adult Patients With Active Lupus Nephritis IND
- Berotralstat
- Elobixibat
- Emapalumab
- Forigerimod
- Imlifidase
- Lanadelumab
- Lesinurad / allopurinol
- Naldemedine
- RP-L201
- Teprasiran
- Teprotumumab
- Triamcinolone
- Voclosporin
Darmziekten
Hart- en vaatziekten
Huidziekten
- Abrocitinib
- Baricitinib IND
- Bimekizumab
- Clascoterone
- Crisaborole
- Difelikefalin
- Glycopyrronium tosylate
- Ixekizumab IND
- Lebrikizumab
- Ligelizumab
- Nemolizumab
- Omalizumab IND
- Risankizumab
- Secukinumab IND
-
Tapinarof
- Tildrakizumab
- Tirbanibulin
- Tralokinumab
- Trifarotene
- Upadacitinib IND
- Ustekinumab IND
Reuma
- Anifrolumab
- Filgotinib
- Guselkumab IND
- Ixekizumab IND
- Olokizumab
- Secukinumab IND
- Tocilizumab BS
- Tofacitinib IND
-
Upadacitinib
- Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Rinvoq may be used as monotherapy or in combination with methotrexate.
- Ankylosing Spondylitis IND
- Patients With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD). IND
- Ustekinumab IND